|1.||Nakamura, K: 5 articles (10/2001 - 03/2000)|
|2.||Gabryel, Bozena: 3 articles (09/2005 - 09/2002)|
|3.||Shirane, M: 3 articles (10/2001 - 03/2000)|
|4.||Suppiramaniam, Vishnu: 2 articles (04/2008 - 06/2007)|
|5.||Wijayawardhane, Nayana: 2 articles (04/2008 - 06/2007)|
|6.||Vaglenova, Julia: 2 articles (04/2008 - 06/2007)|
|7.||Nakamura, Kazuo: 2 articles (03/2002 - 01/2002)|
|8.||Kurasawa, M: 2 articles (05/2001 - 08/2000)|
|9.||Zappalà, M: 2 articles (12/2000 - 07/2000)|
|10.||De Sarro, A: 2 articles (12/2000 - 07/2000)|
01/01/1984 - "The hypoxia model in human psychopharmacology: neurophysiological and psychometric studies with aniracetam i.v."
01/01/1984 - "Aniracetam i.v. attenuated the hypoxia-induced deterioration of brain function and mental performance, thus exhibiting protective properties against hypoxia in man. "
04/01/1986 - "Vinpocetine (PED = 3 mg/kg PO) and aniracetam (PED = 30 mg/kg PO) were also effective in preventing disruption of passive avoidance retention impaired by 7% oxygen hypoxia. "
09/01/1990 - "Bifemelane (100-300 mg/kg, p.o.) was protective against these models except for hypobaric hypoxia, and the effects of piracetam, aniracetam and pramiracetam (1000 mg/kg, p.o.) were variable depending on the type of anoxia model used. "
04/01/1986 - "Vinpocetine, vincamine, aniracetam, and Hydergine, compounds with purported cognition activating activity, were evaluated for their ability to prevent scopolamine-induced and hypoxia-induced impairment of passive avoidance retention (24 hr) in rats. "
|2.||Alzheimer Disease (Alzheimer's Disease)
03/01/1994 - "Results from trials in elderly patients with mild to moderate cognitive impairment due to senile dementia of the Alzheimer type suggest that aniracetam may be of benefit, with further trials required to confirm its efficacy profile and to define more precisely those patients most likely to respond to treatment. "
01/01/2007 - "The present findings suggest that aniracetam restores age- and Abeta-induced alterations in membrane fluidity or Abeta-induced increase in [Ca(2+)]i, demonstrating a possible beneficial role of aniracetam in the clinic treatment for senile dementia or Alzheimer's disease."
03/01/1994 - "Preliminary evidence of the potential benefits and good tolerability profile of aniracetam support continued evaluation of its use in patients with mild to moderate senile dementia of the Alzheimer type."
01/01/1987 - "Forty-four patients with senile dementia of the Alzheimer type were randomly allocated into double-blind treatment with either aniracetam (RO 13-5057) 1 g or placebo daily for 3 months. "
01/01/1987 - "Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent."
09/01/2005 - "The current study was conducted to examine potential effect of aniracetam on PI-TPalpha expression and to characterize the PI-TPalpha isoform distribution between membrane and cytosol fractions of astrocytes exposed to simulated ischemia in vitro. "
06/28/2004 - "The present study focused on the mechanism of cytoprotective effect of aniracetam on the primary rat astrocyte cultures exposed to simulated ischemia conditions in vitro. "
09/01/2002 - "Treatment of the cultures with aniracetam (1, 10 and 100 mM) during 24 h ischemia simulated in vitro significantly decreased the number of apoptotic cells. "
09/01/2002 - "Aniracetam attenuates apoptosis of astrocytes subjected to simulated ischemia in vitro."
03/27/2003 - "The results suggest that these effects might be due to a partial calcium agonist activity of aniracetam, and that the effects of aniracetam on amino acid levels might be a mechanism of protection against delayed neuronal death in the ischemic hippocampus, thereby improving memory dysfunction induced by ischemia/reperfusion."
04/01/2012 - "The comparison between aniracetam and ChEIs in patients with relatively mild dementia (15 ≤ MMSE ≤ 25) revealed a significantly better cognitive performance with aniracetam at 6 months and improved functionality at 3 months. "
04/01/2012 - "In the present study, we aimed to evaluate the efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors (ChEIs), in terms of several neuropsychological parameters, in a considerable number of patients with dementia. "
01/01/2002 - "Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease. "
04/01/2001 - "Because the cholinergic system plays an important role in cognitive functions and Alzheimer's disease dementia, the present study was conducted to elucidate the mechanism of action of nefiracetam and aniracetam on neuronal nicotinic acetylcholine receptors (nnAChRs). "
|5.||Amnesia (Dissociative Amnesia)
01/01/1997 - "In contrast, aniracetam (50 mg/kg, for 10 days) produced beneficial effects in the radial maze test in rats with entorhinal cortex lesions, but given at the same dose acutely did not influence scopolamine-induced amnesia. "
02/01/1995 - "In a dose-response experiment it was demonstrated that 50 mg kg-1 was the lowest oral dose of aniracetam to significantly ameliorate scopolamine-induced amnesia. "
02/01/1995 - "The pyrrolidinone derivative aniracetam given orally immediately after acquisition of an inhibitory avoidance response reproducibly ameliorated scopolamine-induced amnesia in female rats in an extensive series of test sessions conducted over a 1-year period. "
06/01/1990 - "These results suggest that BY-1949, as well as aniracetam, exerts some improvement effects on experimental amnesia."
03/20/1990 - "Aniracetam failed to improve the picrotoxin-induced amnesia. "
|2.||Cholinesterase Inhibitors (Anticholinesterases)
|4.||Nootropic Agents (Nootropics)
|1.||Activities of Daily Living (ADL)